

Formulary Update

January 2021

The following changes to the Adult Medicines Formulary have been agreed during the ADTC or sub-committee meetings since December 2020. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Paramax®	Migraine	4.7.4.1	Tablets and powder formulations discontinued in UK
Methylcellulose	Anti-obesity medication	4.5.1	Product discontinued in UK

Additions	Indication	Adult Medicines Formulary entry/ rationale	
-----------	------------	--	--

Changes in preferred brand	New preferred brand	Adult Medicines Formulary entry	
----------------------------	---------------------	---------------------------------	--

Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Semi-sodium valproate/ sodium valproate	New prescribing notes added	4.8.1	Formulary appeal
Temocillin	Restrictions updated in line with new antimicrobial guidelines	5.1.1.2	Formulary appeal
Monofer® and Diafer®	Change of generic name according to global nomenclature from iron isomaltoside to ferric derisomaltose	9.1.1.2	Pharmaceutical industry decision

Contact us [here](#)